Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity

mBio

Volumn 6, Issue 2, 2015, Pages

  Goneau, Lee W ^a,b,c   Hannan, Thomas J ^d   Macphee, Roderick A ^c   Schwartz, Drew J ^d   Macklaim, Jean M ^b   Gloor, Gregory B ^b   Razvi, Hassan ^b   Reid, Gregor ^b,c   Hultgren, Scott J ^d   Burton, Jeremy P ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADHESIN; CIPROFLOXACIN; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL VIRULENCE; BIOFILM; BLADDER; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; IMMUNITY; KIDNEY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAPHYLOCOCCUS SAPROPHYTICUS; URINARY TRACT INFECTION; ANIMAL; BACTERIAL INFECTIONS; BACTERIUM ADHERENCE; C3H MOUSE; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PROCEDURES; RECURRENT DISEASE; URINARY TRACT INFECTIONS; VIRULENCE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MURINAE; MUS; STAPHYLOCOCCUS SAPROPHYTICUS;

ADHESINS, BACTERIAL; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BACTERIAL INFECTIONS; BIOFILMS; DISEASE MODELS, ANIMAL; DRUG THERAPY; ESCHERICHIA COLI; FEMALE; KIDNEY; MICE, INBRED C3H; MICE, INBRED C57BL; RECURRENCE; STAPHYLOCOCCUS SAPROPHYTICUS; URINARY BLADDER; URINARY TRACT INFECTIONS; VIRULENCE;

EID: 84928794873     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.00356-15     Document Type: Article

References (87)

1. Davies J, Spiegelman GB, Yim G. 2006. The world of subinhibitory antibiotic concentrations. Curr Opin Microbiol 9:445–453. http://dx.doi.org/10.1016/j.mib.2006.08.006.
2. Goh EB, Yim G, Tsui W, McClure J, Surette MG, Davies J. 2002. Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics. Proc Natl Acad Sci U S A 99:17025–17030. http://dx.doi.org/10.1073/pnas.252607699.
3. Hoffman LR, D’Argenio DA, MacCoss MJ, Zhang Z, Jones RA, Miller SI. 2005. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 436:1171–1175. http://dx.doi.org/10.1038/nature03912.
4. Kelley WL. 2006. Lex marks the spot: the virulent side of SOS and a closer look at the LexA regulon. Mol Microbiol 62:1228–1238. http://dx.doi.org/10.1111/j.1365-2958.2006.05444.x.
5. Li H, Xu L, Wang J, Wen Y, Vuong C, Otto M, Gao Q. 2005. Conversion of Staphylococcus epidermidis strains from commensal to invasive by expression of the ica locus encoding production of biofilm exopolysaccharide. Infect Immun 73:3188–3191. http://dx.doi.org/10.1128/IAI.73.5.3188-3191.2005.
6. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, Peters G, Karch H. 2012. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 56:3277–3282. http://dx.doi.org/10.1128/AAC.06315-11.
7. Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y, Reverdy ME, Vandenesch F, Etienne J, Lina G. 2007. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother 51:1515–1519. http://dx.doi.org/10.1128/AAC.01201-06.
8. Goerke C, Köller J, Wolz C. 2006. Ciprofloxacin and trimethoprim cause phage induction and virulence modulation in Staphylococcus aureus. Antimicrob Agents Chemother 50:171–177. http://dx.doi.org/10.1128/AAC.50.1.171-177.2006.
9. Kernodle DS, McGraw PA, Barg NL, Menzies BE, Voladri RK, Harshman S. 1995. Growth of Staphylococcus aureus with nafcillin in vitro induces alpha-toxin production and increases the lethal activity of sterile broth filtrates in a murine model. J Infect Dis 172:410–419. http://dx.doi.org/10.1093/infdis/172.2.410.
10. Nerandzic MM, Donskey CJ. 2011. Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice. Antimicrob Agents Chemother 55:2174–2177. http://dx.doi.org/10.1128/AAC.01612-10.
11. Ohlsen K, Ziebuhr W, Koller KP, Hell W, Wichelhaus TA, Hacker J. 1998. Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 42: 2817–2823.
12. Otto MP, Martin E, Badiou C, Lebrun S, Bes M, Vandenesch F, Etienne J, Lina G, Dumitrescu O. 2013. Effects of subinhibitory concentrations of antibiotics on virulence factor expression by community-acquired methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 68: 1524–1532. http://dx.doi.org/10.1093/jac/dkt073.
13. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. 2007. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 195:202–211. http://dx.doi.org/10.1086/510396.
14. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. 2000. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 342:1930–1936. http://dx.doi.org/10.1056/NEJM200006293422601.
15. Culić O, Eraković V, Parnham MJ. 2001. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 429:209–229. http://dx.doi.org/10.1016/S0014-2999(01)01321-8.
16. Dalhoff A, Shalit I. 2003. Immunomodulatory effects of quinolones. Lancet Infect Dis 3:359–371. http://dx.doi.org/10.1016/S1473-3099(03)00658-3.
17. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. 2003. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 31:2742–2751. http://dx.doi.org/10.1097/01.CCM.0000098031.24329.10.
18. Madden T, Doble A, Aliyu SH, Neal DE. 2011. Infective complications after transrectal ultrasound-guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospital-acquired infections. BJU Int 108:1597–1602. http://dx.doi.org/10.1111/j.1464-410X.2011.10160.x.
19. Miliani K, L’Hériteau F, Astagneau P, INCISO Network Study Group. 2009. Non-compliance with recommendations for the practice of antibiotic prophylaxis and risk of surgical site infection: results of a multilevel analysis from the INCISO Surveillance Network. J Antimicrob Chemother 64:1307–1315. http://dx.doi.org/10.1093/jac/dkp367.
20. Namias N, Harvill S, Ball S, McKenney MG, Salomone JP, Civetta JM. 1999. Cost and morbidity associated with antibiotic prophylaxis in the ICU. J Am Coll Surg 188:225–230. http://dx.doi.org/10.1016/S1072-7515(98)00287-7.
21. Patel U, Dasgupta P, Amoroso P, Challacombe B, Pilcher J, Kirby R. 2012. Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. Bju Int 109:1781–1785. http://dx.doi.org/10.1111/j.1464-410X.2011.10561.x.
22. Schappert SM, Rechtsteiner EA. 2011. Ambulatory medical care utilization estimates for 2007. National Center for Health Statistics, Hyattsville, MD. Vital Health Stat 13(169):1–38.
23. Foxman B. 2010. The epidemiology of urinary tract infection. Nat Rev Urol 7:653–660. http://dx.doi.org/10.1038/nrurol.2010.190.
24. Gupta K, Hooton TM, Stamm WE. 2001. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med 135:41–50. http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00012.
25. Ikäheimo R, Siitonen A, Heiskanen T, Kärkkäinen U, Kuosmanen P, Lipponen P, Mäkelä PH. 1996. Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 22:91–99. http://dx.doi.org/10.1093/clinids/22.1.91.
26. RIVUR Trial Investigators, Hoberman A, Greenfield SP, Mattoo TK, Keren R, Mathews R, Pohl HG, Kropp BP, Skoog SJ, Nelson CP, Moxey-Mims M, Chesney RW, Carpenter MA. 2014. Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med 370: 2367–2376. http://dx.doi.org/10.1056/NEJMoa1401811.
27. Nickel JC. 2005. Practical management of recurrent urinary tract infections in premenopausal women. Rev Urol 7:11–17.
28. Conway PH, Cnaan A, Zaoutis T, Henry BV, Grundmeier RW, Keren R. 2007. Recurrent urinary tract infections in children: risk factors and association with prophylactic antimicrobials. JAMA 298:179–186. http://dx.doi.org/10.1001/jama.298.2.179.
29. Raz R, Colodner R, Kunin CM. 2005. Who are you—Staphylococcus saprophyticus? Clin Infect Dis 40:896–898. http://dx.doi.org/10.1086/428353.
30. Buchanan K, Falkow S, Hull RA, Hull SI. 1985. Frequency among Enterobacteriaceae of the DNA sequences encoding type 1 pili. J Bacteriol 162:799–803.
31. Keith BR, Maurer L, Spears PA, Orndorff PE. 1986. Receptor-binding function of type 1 pili effects bladder colonization by a clinical isolate of Escherichia coli. Infect Immun 53:693–696.
32. Anderson GG, Palermo JJ, Schilling JD, Roth R, Heuser J, Hultgren SJ. 2003. Intracellular bacterial biofilm-like pods in urinary tract infections. Science 301:105–107. http://dx.doi.org/10.1126/science.1084550.
33. Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. 2012. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic Escherichia coli bladder infection. FEMS Microbiol Rev 36:616–648. http://dx.doi.org/10.1111/j.1574-6976.2012.00339.x.
34. Mulvey MA, Lopez-Boado YS, Wilson CL, Roth R, Parks WC, Heuser J, Hultgren SJ. 1998. Induction and evasion of host defenses by type 1-piliated uropathogenic Escherichia coli. Science 282:1494–1497. http://dx.doi.org/10.1126/science.282.5393.1494.
35. Nagamatsu K, Hannan TJ, Guest RL, Kostakioti M, Hadjifrangiskou M, Binkley J, Dodson K, Raivio TL, Hultgren SJ. 2015. Dysregulation of Escherichia coli alpha-hemolysin expression alters the course of acute and persistent urinary tract infection. Proc Natl Acad Sci USA 112:E871–E880 http://dx.doi.org/10.1073/pnas.1500374112.
36. Schwartz DJ, Chen SL, Hultgren SJ, Seed PC. 2011. Population dynamics and niche distribution of uropathogenic Escherichia coli during acute and chronic urinary tract infection. Infect Immun 79:4250–4259. http://dx.doi.org/10.1128/IAI.05339-11.
37. Schwartz DJ, Conover MS, Hannan TJ, Hultgren SJ. 2015. Uropathogenic Escherichia coli superinfection enhances the severity of mouse bladder infection. PLoS Pathog 11:e1004599. http://dx.doi.org/10.1371/journal.ppat.1004599.
38. Blango MG, Mulvey MA. 2010. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 54:1855–1863. http://dx.doi.org/10.1128/AAC.00014-10.
39. Mysorekar IU, Hultgren SJ. 2006. Mechanisms of uropathogenic Escherichia coli persistence and eradication from the urinary tract. Proc Natl Acad Sci U S A 103:14170–14175. http://dx.doi.org/10.1073/pnas.0602136103.
40. Schilling JD, Lorenz RG, Hultgren SJ. 2002. Effect of trimethoprim-sulfamethoxazole on recurrent bacteriuria and bacterial persistence in mice infected with uropathogenic Escherichia coli. Infect Immun 70: 7042–7049. http://dx.doi.org/10.1128/IAI.70.12.7042-7049.2002.
41. Sivick KE, Mobley HL. 2010. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun 78:568–585. http://dx.doi.org/10.1128/IAI.01000-09.
42. Hansson S, Hanson E, Hjälmås K, Hultengren M, Jodal U, Olling S, Svanborg-Edén C. 1990. Follicular cystitis in girls with untreated asymptomatic or covert bacteriuria. J Urol 143:330–332.
43. Schlager TA, LeGallo R, Innes D, Hendley JO, Peters CA. 2011. B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J Urol 186:2359–2364. http://dx.doi.org/10.1016/j.juro.2011.07.114.
44. Hannan TJ, Mysorekar IU, Hung CS, Isaacson-Schmid ML, Hultgren SJ. 2010. Early severe inflammatory responses to uropathogenic E. coli predispose to chronic and recurrent urinary tract infection. PLoS Pathog 6:e1001042. http://dx.doi.org/10.1371/journal.ppat.1001042.
45. Justice SS, Hunstad DA, Seed PC, Hultgren SJ. 2006. Filamentation by Escherichia coli subverts innate defenses during urinary tract infection. Proc Natl Acad Sci U S A 103:19884–19889. http://dx.doi.org/10.1073/pnas.0606329104.
46. Ingersoll MA, Kline KA, Nielsen HV, Hultgren SJ. 2008. G-CSF induction early in uropathogenic Escherichia coli infection of the urinary tract modulates host immunity. Cell Microbiol 10:2568–2578. http://dx.doi.org/10.1111/j.1462-5822.2008.01230.x.
47. Schilling JD, Mulvey MA, Hultgren SJ. 2001. Dynamic interactions between host and pathogen during acute urinary tract infections. Urology 57:56–61. http://dx.doi.org/10.1016/S0090-4295(01)01130-X.
48. Li B, Smith P, Horvath DJ, Jr., Romesberg FE, Justice SS. 2010. SOS regulatory elements are essential for UPEC pathogenesis. Microbes Infect 12:662–668. http://dx.doi.org/10.1016/j.micinf.2010.04.009.
49. Bisognano C, Vaudaux P, Rohner P, Lew DP, Hooper DC. 2000. Induction of fibronectin-binding proteins and increased adhesion of quinolone-resistant Staphylococcus aureus by subinhibitory levels of ciprofloxacin. Antimicrob Agents Chemother 44:1428–1437. http://dx.doi.org/10.1128/AAC.44.6.1428-1437.2000.
50. Denève C, Bouttier S, Dupuy B, Barbut F, Collignon A, Janoir C. 2009. Effects of subinhibitory concentrations of antibiotics on colonization factor expression by moxifloxacin-susceptible and moxifloxacin-resistant Clostridium difficile strains. Antimicrob Agents Chemother 53: 5155–5162. http://dx.doi.org/10.1128/AAC.00532-09.
51. Rasigade JP, Moulay A, Lhoste Y, Tristan A, Bes M, Vandenesch F, Etienne J, Lina G, Laurent F, Dumitrescu O. 2011. Impact of subinhibitory antibiotics on fibronectin-mediated host cell adhesion and invasion by Staphylococcus aureus. BMC Microbiol 11:263. http://dx.doi.org/10.1186/1471-2180-11-263.
52. Garin EH, Olavarria F, Garcia Nieto V, Valenciano B, Campos A, Young L. 2006. Clinical significance of primary vesicoureteral reflux and urinary antibiotic prophylaxis after acute pyelonephritis: a multicenter, randomized, controlled study. Pediatrics 117:626–632. http://dx.doi.org/10.1542/peds.2005-1362.
53. Garnica M, Nouér SA, Pellegrino FL, Moreira BM, Maiolino A, Nucci M. 2013. Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance. BMC Infect Dis 13:356. http://dx.doi.org/10.1186/1471-2334-13-356.
54. Mattoo TK. 2009. Are prophylactic antibiotics indicated after a urinary tract infection? Curr Opin Pediatr 21:203–206. http://dx.doi.org/10.1097/MOP.0b013e3283257d0f.
55. King NP, Beatson SA, Totsika M, Ulett GC, Alm RA, Manning PA, Schembri MA. 2011. UafB is a serine-rich repeat adhesin of Staphylococcus saprophyticus that mediates binding to fibronectin, fibrinogen and human uroepithelial cells. Microbiology 157:1161–1175. http://dx.doi.org/10.1099/mic.0.047639-0.
56. Kline KA, Ingersoll MA, Nielsen HV, Sakinc T, Henriques-Normark B, Gatermann S, Caparon MG, Hultgren SJ. 2010. Characterization of a novel murine model of Staphylococcus saprophyticus urinary tract infection reveals roles for Ssp and SdrI in virulence. Infect Immun 78: 1943–1951. http://dx.doi.org/10.1128/IAI.01235-09.
57. Matsuoka E, Tanaka Y, Kuroda M, Shouji Y, Ohta T, Tanaka I, Yao M. 2011. Crystal structure of the functional region of Uro-adherence factor A from Staphylococcus saprophyticus reveals participation of the B domain in ligand binding. Protein Sci 20:406–416. http://dx.doi.org/10.1002/pro.573.
58. Hadjifrangiskou M, Gu AP, Pinkner JS, Kostakioti M, Zhang EW, Greene SE, Hultgren SJ. 2012. Transposon mutagenesis identifies uropathogenic Escherichia coli biofilm factors. J Bacteriol 194:6195–6205. http://dx.doi.org/10.1128/JB.01012-12.
59. Martinez JJ, Mulvey MA, Schilling JD, Pinkner JS, Hultgren SJ. 2000. Type 1 pilus-mediated bacterial invasion of bladder epithelial cells. EMBO J 19:2803–2812. http://dx.doi.org/10.1093/emboj/19.12.2803.
60. Wright KJ, Seed PC, Hultgren SJ. 2007. Development of intracellular bacterial communities of uropathogenic Escherichia coli depends on type 1 pili. Cell Microbiol 9:2230–2241. http://dx.doi.org/10.1111/j.1462-5822.2007.00952.x.
61. Brook I, Hausfeld JN. 2006. In vitro effects of penicillin and telithromycin on the expression of Streptococcus pneumoniae capsule. J Antimicrob Chemother 58:678–679. http://dx.doi.org/10.1093/jac/dkl261.
62. Schembri MA, Blom J, Krogfelt KA, Klemm P. 2005. Capsule and fimbria interaction in Klebsiella pneumoniae. Infect Immun 73: 4626–4633. http://dx.doi.org/10.1128/IAI.73.8.4626-4633.2005.
63. Justice SS, Hung C, Theriot JA, Fletcher DA, Anderson GG, Footer MJ, Hultgren SJ. 2004. Differentiation and developmental pathways of uropathogenic Escherichia coli in urinary tract pathogenesis. Proc Natl Acad Sci U S A 101:1333–1338. http://dx.doi.org/10.1073/pnas.0308125100.
64. Justice SS, Hunstad DA, Cegelski L, Hultgren SJ. 2008. Morphological plasticity as a bacterial survival strategy. Nat Rev Microbiol 6:162–168. http://dx.doi.org/10.1038/nrmicro1820.
65. Blaine TA, Pollice PF, Rosier RN, Reynolds PR, Puzas JE, O’Keefe RJ. 1997. Modulation of the production of cytokines in titanium-stimulated human peripheral blood monocytes by pharmacological agents. The role of cAMP-mediated signaling mechanisms. J Bone Joint Surg Am 79: 1519–1528.
66. Ono Y, Ohmoto Y, Ono K, Sakata Y, Murata K. 2000. Effect of grepafloxacin on cytokine production in vitro. J Antimicrob Chemother 46: 91–94. http://dx.doi.org/10.1093/jac/46.1.91.
67. Bishop BL, Duncan MJ, Song J, Li G, Zaas D, Abraham SN. 2007. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat Med 13:625–630. http://dx.doi.org/10.1038/nm1572.
68. Hang L, Haraoka M, Agace WW, Leffler H, Burdick M, Strieter R, Svanborg C. 1999. Macrophage inflammatory protein-2 is required for neutrophil passage across the epithelial barrier of the infected urinary tract. J Immunol 162:3037–3044.
69. Hannan TJ, Roberts PL, Riehl TE, van der Post S, Binkley JM, Schwartz DJ, Miyoshi H, Mack M, Schwendener RA, Hooton TM, Stappenbeck TS, Hansson GC, Stenson WF, Colonna M, Stapleton AE, Hultgren SJ. 2014. Inhibition of cyclooxygenase-2 prevents chronic and recurrent cystitis. EBio- Medicine 1:46–57. http://dx.doi.org/10.1016/j.ebiom.2014.10.011.
70. Hedges S, Agace W, Svensson M, Sjögren AC, Ceska M, Svanborg C. 1994. Uroepithelial cells are part of a mucosal cytokine network. Infect Immun 62:2315–2321.
71. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. 1991. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174: 1209–1220. http://dx.doi.org/10.1084/jem.174.5.1209.
72. Duell BL, Carey AJ, Tan CK, Cui X, Webb RI, Totsika M, Schembri MA, Derrington P, Irving-Rodgers H, Brooks AJ, Cripps AW, Crowley M, UlettGC. 2012. Innate transcriptional networks activated in bladder in response to uropathogenic Escherichia coli drive diverse biological pathways and rapid synthesis of IL-10 for defense against bacterial urinary tract infection. J Immunol 188:781–792. http://dx.doi.org/10.4049/jimmunol.1101231.
73. Mosser DM. 2003. The many faces of macrophage activation. J Leukoc Biol 73:209–212. http://dx.doi.org/10.1189/jlb.0602325.
74. Boneberg EM, Hartung T. 2002. Granulocyte colony-stimulating factor attenuates LPS-stimulated IL-1β release via suppressed processing of proIL-1β, whereas TNF-α release is inhibited on the level of pro-TNF-α formation. Eur J Immunol 32:1717–1725. http://dx.doi.org/10.1002/1521-4141(200206)32:6_1717::AID-IMMU1717_3.0.CO;2-N.
75. Kim SO, Sheikh HI, Ha SD, Martins A, Reid G. 2006. G-CSF-mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosusinduced suppression of TNF production in macrophages. Cell Microbiol 8:1958–1971. http://dx.doi.org/10.1111/j.1462-5822.2006.00763.x.
76. Enzler MJ, Berbari E, Osmon DR. 2011. Antimicrobial prophylaxis in adults. Mayo Clin Proc 86:686–701. http://dx.doi.org/10.4065/mcp.2011.0012.
77. Garofalo CK, Hooton TM, Martin SM, Stamm WE, Palermo JJ, Gordon JI, Hultgren SJ. 2007. Escherichia coli from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation. Infect Immun 75:52–60. http://dx.doi.org/10.1128/IAI.01123-06.
78. Wright KJ, Seed PC, Hultgren SJ. 2005. Uropathogenic Escherichia coli flagella aid in efficient urinary tract colonization. Infect Immun 73: 7657–7668. http://dx.doi.org/10.1128/IAI.73.11.7657-7668.2005.
79. Kuroda M, Yamashita A, Hirakawa H, Kumano M, Morikawa K, Higashide M, Maruyama A, Inose Y, Matoba K, Toh H, Kuhara S, Hattori M, Ohta T. 2005. Whole genome sequence of Staphylococcus saprophyticus reveals the pathogenesis of uncomplicated urinary tract infection. Proc Natl Acad Sci U S A 102:13272–13277. http://dx.doi.org/10.1073/pnas.0502950102.
80. Salit IE, Gotschlich EC. 1977. Hemagglutination by purified type I Escherichia coli pili. J Exp Med 146:1169–1181. http://dx.doi.org/10.1084/jem.146.5.1169.
81. Croze OA, Ferguson GP, Cates ME, Poon WC. 2011. Migration of chemotactic bacteria in soft agar: role of gel concentration. Biophys J 101:525–534. http://dx.doi.org/10.1016/j.bpj.2011.06.023.
82. Hung CS, Dodson KW, Hultgren SJ. 2009. A murine model of urinary tract infection. Nat Protoc 4:1230–1243. http://dx.doi.org/10.1038/nprot.2009.116.
83. Goneau LW, Yeoh NS, MacDonald KW, Cadieux PA, Burton JP, Razvi H, Reid G. 2014. Selective target inactivation rather than global metabolic dormancy causes antibiotic tolerance in uropathogens. Antimicrob Agents Chemother 58:2089–2097. http://dx.doi.org/10.1128/AAC.02552-13.
84. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. 2007. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 4:e329. http://dx.doi.org/10.1371/journal.pmed.0040329.
85. Fernandes AD, Macklaim JM, Linn TG, Reid G, Gloor GB. 2013. ANOVA-like differential expression (ALDEx) analysis for mixed population RNA-Seq. PLoS One 8:e67019. http://dx.doi.org/10.1371/journal.pone.0067019.
86. Fernandes AD, Reid JN, Macklaim JM, McMurrough TA, Edgell DR, Gloor GB. 2014. Unifying the analysis of high-throughput sequencing datasets: characterizing RNA-seq, 16S rRNA gene sequencing and selective growth experiments by compositional data analysis. Microbiome 2:15. http://dx.doi.org/10.1186/2049-2618-2-15.
87. Macklaim JM, Fernandes AD, Di Bella JM, Hammond JA, Reid G, Gloor GB. 2013. Comparative meta-RNA-seq of the vaginal microbiota and differential expression by Lactobacillus iners in health and dysbiosis. Microbiome 1:12. http://dx.doi.org/10.1186/2049-2618-1-12.